Clinical Trial

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-15; most recent amendment 2026-03-02.
Trial Details
NCT Number NCT07137481
Lead Sponsor M.D. Anderson Cancer Center
Conditions Hematological Malignancies
Enrollment 70 participants
Start Date 2027-02-28
Primary Completion 2030-07-31 (estimated)
Study Completion 2032-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30